An interventional study of Specialized Unit and Usual Follow-Up in Hepatic Steatosis, sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. Withdrawn at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Consorci Sanitari de l'Alt Penedès i Garraf · Not applicable, Interventional, and Supportive care
Funding issues
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Fatty Liver with a site in Spain — 11 open to participants now, 12 under way, 4 of them phase 3. Fatty Liver · Spain.
Among the 28 studies in Fatty Liver with a site in Spain, this one is the 23rd largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 12 with no phase, and was the 19th registered.
666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.
Browse Fatty Liver studies →11 of the 28 studies in Fatty Liver with a site in Spain are open now. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 20–80
Consorcio Centro de Investigación Biomédica en Red (CIBER) · Sites in Spain
Ages 40+
Eli Lilly and Company · Sites in Spain, United States, Argentina and 31 more countries
Ages 18+
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 18–75
Boehringer Ingelheim · Sites in Spain, United States, Argentina and 34 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 165 across the 23 interventional studies, 450 across the 5 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 28 have an industry lead sponsor. The 10 most frequent:
Consorci Sanitari de l'Alt Penedès i Garraf is the lead sponsor of 45 studies on the registry; 21 are open to participants now.
Consorci Sanitari de l'Alt Penedès i Garraf has 2 studies filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
3 of the studies in Fatty Liver with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07652892Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauImpact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective. | 2027-02-25 |
| NCT07467512Consorcio Centro de Investigación Biomédica en Red (CIBER)Exercise for an Aging Liver (EXALIVER) | 2027-06 |
| NCT06613698GlaxoSmithKlineA Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease | 2027-11-26 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Fatty Liver with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this clinical trial is to determine whether a specialized consultation for controlling metabolic syndrome effectively treats hepatic steatosis in adults. The primary questions it aims to answer are:
The improvement of the disease will be assessed through the following parameters:
Participants will be randomly assigned to two groups. The first group will be visited in the specialized consultation every three months for one year and will continue to receive the rest of their follow-up visits. The second group will undergo their usual follow-up visits but will not be visited in the specialized consultation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group of participants will be visited in the specialized consultation and will continue to receive the rest of their follow-up visits.
Other: Specialized Unit · Other: Usual Follow-Up
This group of participants will undergo their usual follow-up visits but will not be visited in the specialized consultation.
Other: Usual Follow-Up
The participant will be visited every three months for one year
The participant will be visited as usual, it means they will be visited at Digestive Consultation
Discharge criteria from the gastroenterology clinic
Percentage of patients meeting discharge criteria (defined by the trial) from the gastroenterology clinic at the end of the study
Time frame: 1 year
Discharge from the gastroenterology clinic after achieving metabolic control goals
Difference in the percentage of patients discharged from the gastroenterology clinic after achieving metabolic control goals
Time frame: 1 year
Change on Test de Owliver
Change in the Owliver test compared to baseline
Time frame: 1 year
Change on liver enzymes
Change compared to baseline in the liver enzymes (UI/mL)
Time frame: 1 year
Change on total cholesterol
Change compared to baseline in the total cholesterol (mg/dL)
Time frame: 1 year
Change on LDL- cholesterol
Change compared to baseline in the LDL- cholesterol (mg/dL)
Time frame: 1 year
Change on HDL- cholesterol
Change compared to baseline in the HDL- cholesterol (mg/dL)
Time frame: 1 year
Change on triglycerides
Change compared to baseline in the triglycerides (mg/dL)
Time frame: 1 year
Change on Fibrosis-4 Index
Change compared to baseline on Fibrosis-4 Index
Time frame: 1 year
Change on Hepatic Fibrosis
Change compared to baseline on Fibroscan score
Time frame: 1 year
Glycated hemoglobin
In diabetic patients, change compared to baseline on glycated hemoglobin
Time frame: 1 yera
Insulin resistance
In patients with insulin resistance, change compared to baseline on Insulin Resistance Index
Time frame: 1 year
Body Mass Index
Change compared to baseline on body mass index
Time frame: 1 year
Plan to share: Yes — IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).
Supporting information: Study protocol, Informed consent form
Time frame: After publication of main results of the study.
Access criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Dec 2027, 24 months later.
How these figures are worked out, and which studies are left out of them.
Funding issues
Funding issues
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Consorci Sanitari de l'Alt Penedès i Garraf